Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen blockade therapy
may lessen the amount of androgens made by the body. Zoledronic acid may help relieve some of
the symptoms caused by bone metastasis. It is not yet known whether androgen-blockade therapy
is more effective with or without zoledronic acid in treating patients with prostate cancer
that has spread to the bone.
PURPOSE: This randomized phase III trial is studying androgen-blockade therapy given together
with zoledronic acid to see how well it works compared with androgen-blockade therapy alone
in treating patients with prostate cancer and bone metastases.
Phase:
Phase 3
Details
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Translational Research Informatics Center, Kobe, Hyogo, Japan